A retrospective review published in the International Journal of Dermatology evaluated the safety of systemic minoxidil, as either low-dose oral or sublingual, in 63 children aged 0-12 years with hair disorders. Two-thirds of patients were treated for alopecia areata and eight patients for loose anagen syndrome. . Most patients started at a dose of 0.1 mg once daily, with dosage up-titrated according to treatment response. The average maximum dose concentration of minoxidil was 12.45 ng/kg, with a treatment duration range of three to 65 months. The mean duration of treatment was 14.6 months. . Mild hypertrichosis was the most common side effect, although none of the side effects required discontinuation or dose adjustment. While low-dose oral minoxidil and sublingual minoxidil were well tolerated, the authors find that future prospective studies that objectively measure the efficacy and optimum dose concentration should be considered. . Visit the link in our bio to learn more in #DermWorldWeekly.